SABCS Snippets: HER2CLIMB-05 Clinical Trial Updates
Oct 17, 2025 · Breast Cancer experts Dr. Erika Hamilton and Dr. Kate Lathrop discuss the recent announcement of results from the HER2CLIMB-05 Trial from PIK3CA Wild-Type Cohort in the …
TUKYSA Added to First-Line Maintenance Therapy Extends Median …
Dec 10, 2025 · TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 …
Study Details | NCT02614794 | A Study of Tucatinib vs. Placebo in ...
Aug 14, 2023 · A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic ...
Dec 11, 2019 · We conducted an international, randomized, double-blind trial in which the combination of tucatinib plus trastuzumab and capecitabine was compared with placebo plus …
Advancing treatment in HER2-positive metastatic breast cancer: …
Jul 7, 2025 · Abstract Tucatinib has significantly advanced the treatment of HER2-positive metastatic breast cancer. When used in combination with trastuzumab and capecitabine, it …
Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial ...
May 2, 2024 · This is the first report of HER2CLIMB-02 (NCT03975647), a randomized, double-blind, placebo-controlled phase 3 study assessing the efficacy and safety of tucatinib …
Key Insights from the HER2CLIMB Trial | CancerNetwork
Nov 25, 2024 · Panelists discuss key data from the HER2CLIMB study, which evaluates the efficacy of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine …
Tucatinib Combinations in HER2+ Breast Cancer: HER2CLIMB-02 …
May 21, 2025 · Panelists discuss how the HER2CLIMB-02 and HER2CLIMB-05 trials might impact treatment sequencing, with particular interest in using tucatinib earlier in treatment to …
Tucatinib versus placebo added to trastuzumab and capecitabine …
Mar 1, 2022 · Patients and methods HER2CLIMB is a randomized, double-blind, placebo-controlled trial in patients with locally advanced or metastatic HER2+ breast cancer, including …
HER2Climb Trial Results: A Comprehensive Analysis
The selection of participants is a defining characteristic of any clinical study. In the HER2Climb trial, inclusion criteria focused on patients aged 18 years or older, diagnosed with HER2 …